| Balance Sheets | 2026-03-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 30,789 | |||
| Marketable securities | 14,614 | |||
| Prepaid expenses and other current assets | 1,540 | |||
| Total current assets | 46,943 | |||
| Property and equipment, net | 427 | |||
| Right-of-use asset - operating lease | 801 | |||
| Other assets | 393 | |||
| Total assets | 48,564 | |||
| Accounts payable | 1,535 | |||
| Accrued expenses | 8,755 | |||
| Notes payable | 96 | |||
| Deferred revenue - current portion | 1,710 | |||
| Less operating lease liabilities - current portion | 699 | |||
| Total current liabilities | 12,795 | |||
| Deferred revenue - non-current portion | 0 | |||
| Operating lease liabilities - non-current portion | 249 | |||
| Total liabilities | 13,044 | |||
| Common stock, 0.001 par value 325,000,000 shares authorized at march31, 2026 and march31, 2025 39,624,839 and 29,001,481 shares issued at march31, 2026 and march31, 2025, respectively | 40 | |||
| Additional paid-in capital | 516,767 | |||
| Treasury stock, at cost, 4,522 shares of common stock held at march31, 2026 and march31, 2025 | 3,968 | |||
| Accumulated other comprehensive gain (loss) | -2 | |||
| Accumulated deficit | -477,317 | |||
| Total stockholders equity | 35,520 | |||
| Total liabilities and stockholders equity | 48,564 | |||
Vistagen Therapeutics, Inc. (VTGN)
Vistagen Therapeutics, Inc. (VTGN)